TRANSDERM-NITRO
LOE ApproachingNDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Oct 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRANSDERM-NITRO is a transdermal nitrate patch delivering nitroglycerin in extended-release form for cardiovascular indications. The product uses a small-molecule approach to provide sustained nitrate therapy through the skin. Specific indication details are not available in the product record.
LOE Approaching
This legacy product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling a mature brand team focused on defending market share rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TRANSDERM-NITRO offers limited growth trajectory but provides solid experience in legacy product management, defensive market positioning, and mature brand operations. Roles focus on maintaining profitability and market share against generics rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on TRANSDERM-NITRO at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.